INmune Bio Inc. INMB
Regular-session close
After hours · Nov 19, 7:51 PM ET
- YTD
- -42.69%
- 1 year
- -40.79%
5D -0.1859 (-17.21%)
- Market cap
- 27.68M
- Revenue (ttm)
- 42.00K
- EPS (ttm)
- -0.53
- Shares out
- 22.17M
- Forward P/E
- -2.23
- YTD return
- -42.69%
- 1-year return
- -40.79%
- 50-day average
- 5.27
- Volume
- 411.63K
- Avg volume
- 341.10K
- Open
- 1.03
- Previous close
- 1.03
- Day's range
- 0.894 – 1.03
- 52-week range
- 0.8941 – 2.51
- Beta
- 1.85
- Price target
- 19.83 (+2118.2%)
Key statistics
- 200-day average
- 7.78
- Enterprise value
- 66.92M
- Price / sales
- 2402.02
- Price / book
- 2.61
- Free cash flow
- -10.76M
- Total cash
- 33.55M
- Total debt
- 2.91M
- Return on equity
- -98.96%
- Short % of float
- 20.96%
Fundamental scorecard
6 of 25 checks passed on INMB’s reported financials
6of 25 checks passed
- Value 1 of 5
- Growth 2 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 31, 2024 | Sep 1, 2024 | -0.49 | -0.60 | -0.11 | -22.45% |
| Aug 1, 2024 | Jun 1, 2024 | 0.00 | -0.50 | — | — |
| Aug 1, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | -0.61 | — | — |
| Mar 28, 2024 | Dec 1, 2023 | 0.00 | -0.47 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 1, 2023 | Baird | init | — | Outperform |
| May 24, 2022 | BTIG | main | — | Buy |
| May 24, 2022 | B. Riley Securities | down | Buy | Neutral |
| Jan 24, 2022 | B. Riley Securities | main | — | Buy |
| Apr 21, 2021 | B. Riley Securities | init | — | Buy |
| Nov 9, 2020 | HC Wainwright & Co. | main | — | Buy |
About INmune Bio Inc.
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- inmunebio.com
News
Freedom Broker Maintains Buy on INmune Bio, Lowers Price Target to $2.5
INmune Bio Inc. (INMB) Q3 2026 Earnings Call Prepared Remarks Transcript
INmune Bio Q3 2026 Earnings Call Transcript INmune Bio Q3 EPS $(0.17) Misses $(0.15) Estimate
INmune Bio Inc. Announces Third Quarter 2026 Results and Provides Business Update
INmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5th
INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement INmune Bio Submits Final Pre-Marketing Authorization Application Package To UK MHRA For Ebstrocel For Recessive Dystrophic Epidermolysis Bullosa; Expects Full MAA Submission In Early February 2027, With Potential UK Approval In Mid-2027; Has Engaged U.S. Regulatory Advisors With Rare Disease Expertise To Prepare And Submit A Type B Meeting Request To FDA
INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027
INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar
Your note
Sign in to keep a note on INMB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| JUDA SCOTT | Director | Purchase | Jun 24, 2024 | 0 |
| LOWDELL MARK WILLIAM | Officer and Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 18, 2024 | 1,510,810 |
| MOSS DAVID J. | Chief Financial Officer | Purchase | Sep 29, 2024 | 1,285,870 |
| SCHROEDER TIMOTHY J | Director | Sale | Jul 11, 2023 | 0 |
| TESI RAYMOND JOSEPH | Chief Executive Officer | Purchase | Sep 11, 2024 | 1,554,110 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 4.24% | 939,468 | 4.27M | Sep 29, 2024 |
| Praetorian Pr LLC | 3.52% | 780,800 | 3.55M | Sep 29, 2024 |
| Vanguard Group Inc | 3.25% | 720,712 | 3.28M | Sep 29, 2024 |
| CVI Holdings, LLC | 2.69% | 596,372 | 2.71M | Jun 29, 2024 |
| Raymond James Financial Services Advisors, Inc. | 1.67% | 369,438 | 1.68M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.55% | 344,466 | 1.57M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.96% | 434,271 | 1.98M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.40% | 310,909 | 1.41M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.75% | 165,874 | 754.73K | Sep 29, 2024 |
| iShares Russell 2000 Growth ETF | 0.59% | 131,179 | 596.86K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.56% | 125,003 | 568.76K | Aug 30, 2024 |
| Fidelity Extended Market Index Fund | 0.34% | 76,154 | 346.50K | Oct 30, 2024 |
